Morgan Stanley Initiates Coverage of REGENXBIO with Buy Rating
Morgan Stanley analyst Maxwell Skor has initiated coverage of REGENXBIO (RGNX) with a Buy rating and a price target of $18.
Stocks · News reference
Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — REGENXBIO Inc. (RGNX)
Filed: 2026-10-16 AccNo: 0001193125-26-423376 Size: 147 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Full Transcript: Regenxbio Q2 2026 Earnings Call
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22
Mizuho analyst Graig Suvannavejh initiates coverage on Regenxbio (NASDAQ:RGNX) with a Outperform rating and announces Price Target of $22.